Sign in Subscribe
Clinical trials

Breakthrough in OBGYN and Reproduction Research: Scientists Discover Promising Treatment for HPV Clearance

Strategic Insights

— 1 min read

Recent study results published in Scientific Reports have provided encouraging insights into the potential efficacy of a novel treatment for human papillomavirus (HPV) clearance and cervical microbiota shift. Researchers conducted a prospective, multi-center, randomized, placebo-controlled trial involving 62 women newly diagnosed with HPV infection without visible cervical lesions. The oral treatment with the strain L. crispatus M247 demonstrated a significant increase in HPV clearance and improved vaginal microbiota composition.

Key Takeaways:

  • The probiotic treatment significantly increased HPV clearance by 60% compared to the control group (31.8%).
  • The treatment also increased the number of negative PAP tests by 83.3% compared to 71.4% in the control group.
  • The vaginal microbiota analysis revealed a significant relationship between HPV clearance and a reduced richness, increased relative presence of L. crispatus, and increased number of women with a CST I microbiota.
  • The research suggests that the oral treatment with L. crispatus M247 could be a promising approach for promoting HPV clearance and improving vaginal microbiota eubiosis.
  • The study highlights the importance of further research to strengthen these findings and explore the mechanisms underlying this potential treatment.

Statistics:

  • 62 women participated in the randomized, multi-center, placebo-controlled trial.
  • 60% of women in the treatment group cleared their HPV infection compared to 31.8% in the control group.
  • 83.3% of women in the treatment group had negative PAP tests compared to 71.4% in the control group.
  • The study provides encouraging insights into the potential efficacy of the oral treatment with L. crispatus M247.

Sources:

  • Effect of orally administered L. crispatus M247 in favoring HR-HPV clearance and CST shift: results from a randomized, multi-center, placebo-controlled trial. Scientific Reports, 2025;15(1):36881.
  • NewsRx. New Findings Reported from Gynecology and Obstetrics Department Describe Advances in OBGYN and Reproduction (Effect of orally administered L. crispatus M247 in favoring HR-HPV clearance and CST shift: results from a randomized, multi-center, ...). Clinical Trials Week. November 3, 2025; p 285.

Read more